Skip to main content
OpenTrials
Completed

NCT Number: NCT06050083

Digital Clinical Hypnosis for Chronic Pain Management

This ClinicalTrials.gov posting contains two randomized controlled trials. The study procedures were identical, except Study 1 was funded by NIH and enrolled adults with chronic low back pain, whereas Study 2 was funded by the UW Department of Rehabilitation Medicine and enrolled adults with any type of chronic pain. Study 1 and 2 each enrolled 50 adults (N = 100 total across the two studies). Although Study 2 did not use NIH funds, we are including the results here because the studies were conducted simultaneously by the same PI (Dr. Jensen) with the same study procedures.

Participants enrolled in the studies for a duration of 8 weeks. The studies test the feasibility and efficacy of a therapeutic hypnosis digital application (website), called Rose. The investigators wanted to determine if the Rose application was user-friendly and effective at improving quality of life and reducing pain for adults with chronic pain. If successfuly, the investigators hope to develop the Rose application into a mobile app that will be publicly available and managed by HypnoScientific Inc., a company that is co-owned by the investigators.

Participants completed brief (15-20min) self-report surveys that ask about pain and mental health at three timepoints: Baseline (week 0), 4 weeks, and 8 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Washington, School of Medicine

Seattle, Washington, 98104, United States

About this study

Pain is a major public health problem that affects over 100 million adults in the United States. While pain can have profound negative impacts, current treatment remains inadequate. A focus on opioid treatments has led to over-prescription, harmful side effects, and the overuse crisis. To address this problem, the study investigators, and others, have developed and adapted hypnosis to empower individuals to self-manage pain. Findings from the investigators' research supports hypnosis as an effective non-pharmacological technique. However, a significant limitation of hypnosis treatment is access, given that hypnosis treatment is provided by a very limited number of clinicians with training in its use, as well as the significant costs of in-person treatment.

The main goal of this study is to pilot test the efficacy of hypnosis content for pain management as provided via recordings in the Rose web application.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(self-report online and telephone screening by study staff):

  • 18 years old or older
  • Chronic Pain or Chronic Low Back Pain (i.e., pain in the low back that has been an ongoing problem for 3 months or more for at least half the days, as disclosed during self-report screening. The pain can be a primary condition or secondary to another health condition.
  • Average pain intensity in the past week ≥ 4 on a 0-10 scale
  • Reads, speaks, and understands English as noted in the medical record or disclosed during self-report screening
  • Has regular access to the internet
  • Has access to devices (phone, desktop, or other) with features (browsers, audio capabilities, etc.) that are congruent with the requirements of the digital therapeutic, as assessed by staff members during self-report screening.

Exclusion criteria

  • History of (within past 5 years) or current diagnosis of primary psychotic or major thought disorder with active symptoms as noted in the medical record or disclosed during self-report screening
  • Psychiatric hospitalization within the past 6 months as noted in the medical record or disclosed during self-report screening
  • Psychiatric or behavioral conditions in which symptoms were unstable or severe within the past 6 months as noted in the medical record or disclosed during self-report screening;
  • Any psychiatric or behavioral issues as noted in the medical record or disclosed/observed during self-report screening that would indicate subject may be inappropriate for study;
  • Presenting symptoms at the time of screening that would interfere with participation, specifically active suicidal ideation with intent to harm oneself or others or active delusional or psychotic thinking;
  • Active malignancy (e.g., cancer not in remission) as noted in the medical record or disclosed during self-report screening;
  • Pain condition for which surgery is recommended and/or planned in the next six months as disclosed during self-report screening;
  • Currently receiving or have received hypnosis treatment for any pain condition as disclosed during self-report screening

Treatment and study plan

Hypnosis audio recordings

Behavioral

A web application (Rose) that contains hypnosis audio recordings created by the investigators.

Primary outcomes

  1. Frequency of Using Rose Application

    Time frame: During the 8 weeks of study participation

    Total # of hypnosis sessions listened to by participants

  2. Continued Interest in Using Rose Application

    Time frame: 8 week assessment

    Participants reporting how interested they would be in continuing to use the Rose application: "If the Rose web/phone application were available to download, how interested would you be in downloading and using this application?" 4 - Extremely interested 3 - Very interested 2 - Somewhat interested

    1 - Little interested 0 - Not interested

  3. Willingness to Pay for Continued Use of Rose Application

    Time frame: 8 week assessment

    Participants that reported a willingness to pay for continued access to the Rose application (results available for Study 2 only): "Would you be willing to pay some amount for a monthly subscription to Rose, to have continued access?"

    1 - Yes 0 - No

  4. Participant Satisfaction

    Time frame: 4 Week, 8 Week timepoints

    Participants answered a Global Satisfaction question about their satisfaction with using the Rose application "Taking all things into account, how satisfied are you with using the Rose web application?" 4 - Very Satisfied 3 - Somewhat Satisfied 2 - Neutral

    1 - Somewhat Dissatisfied 0 - Very Dissatisfied

  5. System Usability Scale (SUS)

    Time frame: 8 Week Timepoint

    Scale title: System Usability Scale. Minimum - Maximum range: 0 to 100. Higher scores indicate more usability (ease of use). There are no subscale scores for this measure.

Secondary outcomes

  1. Average Pain - Past Week

    Time frame: Baseline, 4 Weeks, 8 Weeks

    A 0-10 Numerical Rating scale of average pain in the past week: "Please rate your pain by choosing the one number that best describes your pain at its WORST in the PAST WEEK, where 0 is "no pain" and 10 is "pain as bad as you can imagine"

  2. Worst Pain - Past Week

    Time frame: Baseline, 4 Weeks, 8 Weeks

    A 0-10 Numerical Rating scale of worst pain in the past week: "Please rate your pain by choosing the one number that best describes your pain at its WORST in the PAST WEEK, where 0 is "no pain" and 10 is "pain as bad as you can imagine"

  3. PROMIS Sleep Disturbance Short Form 8a

    Time frame: Baseline (week 0), 4 week assessment, 8 week assessment

    Domain assessed: Sleep Disturbance. Ratings are summed and converted to T scores (Mean = 50 and SD = 10 in the normative sample).

    Higher scores indicate more sleep disturbance. Scores that are >= 55 (i.e., one half a SD above the normative mean) are considered clinically elevated.

  4. PROMIS Pain Interference Short Form

    Time frame: Baseline (week 0), 4 week assessment, 8 week assessment

    Domain assessed: Pain interference. Ratings are summed and converted to T scores (Mean = 50 and SD = 10 in the normative sample).

    Higher scores indicate more pain interference. Scores that are >= 55 (i.e., one half a SD above the normative mean) are considered clinically elevated.

  5. PROMIS Anxiety Short Form 7a

    Time frame: Baseline (week 0), 4 week assessment, 8 week assessment

    Domain assessed: Anxiety. Ratings are summed and converted to T scores (Mean = 50 and SD = 10 in the normative sample).

    Higher scores indicate more anxiety. Scores that are >= 55 (i.e., one half a SD above the normative mean) are considered clinically elevated.

  6. Number of Participants Using Opioids

    Time frame: Baseline (week 0), 4 week assessment, 8 week assessment

    Domain assessed: Opioid Use How assessed: Single item asking participants to indicate whether or not they currently using any opioid mediations.

    Unit of measure is the number and rate of participants who indicated that they are currently using at least one opioid medication.

Sponsors and collaborators

Lead sponsor

University of Washington

Other

Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

Registry information

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Sep 22, 2023
Registry last updated
Jan 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.